<div id="readability-page-1"><p>In a report released today, Judah Frommer from Morgan Stanley maintained a Buy rating on RegenXBio, with a price target of <span id="expert-recommendation-target">$16.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Frommer is a 2-star analyst with an average return of <span>0.7%</span> and a 52.86% success rate. Frommer covers the Healthcare sector, focusing on stocks such as Evommune, Inc., Lakefront Biotherapeutics, and COMPASS Pathways.</p> <p>In addition to Morgan Stanley, RegenXBio also received a Buy from Stifel Nicolaus’s Annabel Samimy in a report issued today. However, yesterday, Goldman Sachs maintained a Hold rating on RegenXBio (NASDAQ: RGNX).</p></div>

RGNX

LABU

<p>Morgan Stanley analyst Judah Frommer has reaffirmed a Buy rating for RegenXBio (RGNX) with a price target of $16.00. Frommer, a 2-star analyst, has a 52.86% success rate. Stifel Nicolaus also issued a Buy rating for RegenXBio, while Goldman Sachs maintained a Hold rating.</p>

Tip Ranks

Regenxbio

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Morgan Stanley

Evommune

Lakefront Biotherapeutics

Compass Pathways

Stifel Financial

Goldman Sachs

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

GS Hldg R

Morgan Stanley Sticks to Its Buy Rating for RegenXBio (RGNX)